Matthew Lunning, DO, FACP, evaluates the clinical trial data from the L-MIND and RE-MIND2 studies, discussing the impact of tafasitamab + lenalidomide on real-world outcomes.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen